<DOC>
	<DOCNO>NCT01276262</DOCNO>
	<brief_summary>A crossover study assess effect repeat dos fostamatinib level oral contraceptive ( Microgynon® 30 ) blood healthy female subject . The study consist screen period 35 day , follow 2 treatment period ( 28 day ) oral contraceptive ( Microgynon® 30 ) absence presence fostamatinib . The study also evaluate safety tolerability fostamatinib combination oral contraceptive</brief_summary>
	<brief_title>Effects Administration Fostamatinib Blood Concentrations Oral Contraceptive Healthy Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Female subject age 18 45 year , inclusive , healthy , nonpregnant , plan pregnancy within study period Willing use highly effective method birth control , ie , double barrier method contraception ( condom diaphragm spermicide ) first day Period 1 28 day last dose Body weight least 50 kg body mass index ( BMI ) 18 30 kg/m2 inclusive Two negative pregnancy test least 7 day apart History clinically significant disease disorder History presence Gastrointestinal , hepatic , renal disease Any condition list contraindication Microgynon® 30 label Absolute neutrophil count le 2.5 x 109/L .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Phase 1 , healthy female volunteer , oral contraceptive , pharmacokinetics , Rheumatoid arthritis , RA , fostamatinib</keyword>
</DOC>